Our mission
To usher in
the Post-Resistance
Era.
By delivering safe, structurally disruptive antimicrobials to millions of patients globally.
No. 01
Disruptive
A multi-site mechanism that resistant bacteria cannot route around.
No. 02
Multi-modal
One engine across antibacterial, antiviral, and angiogenic fronts.
No. 03
Durable
No observed evolutionary resistance across two decades of study.
Advancing care
Defeating
resistance.
Patented methylglyoxal disrupts the bacterial cell wall through a multi-site mechanism pathogens cannot route around, with no evolutionary resistance observed across two decades. The same composition acts against enveloped respiratory viruses at the point of entry.
- Resistant bacteria
- Enveloped viruses
- Tissue repair
- Angiogenesis
The solution
A patented
platform.
Not one molecule, but a patented composition advanced along two parallel regulatory routes. Two independently patented assets, one botanical and one synthetic, multiply delivery options and de-risk the path to the clinic.
No. 01
Cell-wall disruption
Multi-site mechanism resistant bacteria cannot evade.
No. 02
Antiviral action
Active against enveloped respiratory viruses at entry.
No. 03
Tissue repair
Promotes angiogenesis and accelerates wound healing.
No. 04
Expedited routes
Three expedited FDA pathways in play across two assets.
The third front
An effective
angiogenic.
Beyond defeating pathogens, the same composition promotes angiogenesis and accelerates tissue repair through the wound-healing and regenerative pathway.
Medical Grade Manuka, the botanical core of Lepto242, supports the tissue-level conditions necessary for healing, not merely symptom relief.
Continue